[1] Bray F, Ferlay J, Soerjomataram Ⅰ, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2] Isakov N. Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression[J]. Semin Cancer Biol, 2018, 48(2):36-52.
[3] Al-Sanabra O, Duckworth AD, Glenn MA, et al. Transcriptional mechanism of vascular endothelial growth factor-induced expression of protein kinase CbetaII in chronic lymphocytic leukaemia cells[J]. Sci Rep, 2017, 24(7):43228-43240.
[4] Murray NR, Weems J, Braun U, et al. Protein kinase C betaII and PKCiota/lambda: collaborating partners in colon cancer promotion and progression[J]. Cancer Res, 2009, 69(2):656-662.
[5] G?kmen-Polar Y, Mehta R, Tuzmen S, et al. Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes[J]. Breast Cancer Res Treat, 2010, 124(2):327-335.
[6] Chu PY, Hsu NC, Lin SH, et al. High nuclear protein kinase CβⅡ expression is a marker of disease recurrence in oral squamous cell carcinoma[J]. Anticancer Res, 2012, 32(9):3987-3991.
[7] El Osta M, Liu M, Adada M, et al. Sustained PKCβⅡ activity confers oncogenic properties in a phospholipase D-and mTOR-dependent manner [J]. FASEB J, 2014, 28(1):495-505.
[8] He LF, Wang TT, Gao QY, et al. Stanniocalcin-1 promotes tumor angiogenesis through up-regulation of VEGF in gastric cancer cells[J]. J Biomed Sci, 2011, 18(1):39-47.
[9] Duan F, Wu H, Jia D, et al. O-GlcNAcylation of RACK1 promotes hepatocellular carcinogenesis[J]. J Hepatol, 2018, 68(6):1191-1202.
[10] Ruan Y, Sun L, Hao Y, et al. Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma[J]. J Clin Invest, 2012, 122(7):2554-2566.
[11] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1):7-30.
[12] Zheng JX, Zhu Q, Liu Ch, et al. Expression of interleukin-34/colony stimulating factor-1R in the process of transforming growth factor-β1 inducing A549 cells transition[J]. Acta Anatomica Sinica, 2014,45(3):393-397.(in Chinese)
郑金旭,朱勤,刘超,等. 白细胞介素-34/集落刺激因子-1R在转化生长因子-β1诱导A549细胞上皮-间质转化中的表达[J]. 解剖学报,2014, 45(3):393-397.
[13] Gui Y, Khan MGM, Bobbala D, et al. Attenuation of MET-mediated migration and invasion in hepatocellular carcinoma cells by SOCS1[J]. World J Gastroenterol, 2017, 23(36):6639-6649.
[14] Kim DH, Xing T, Yang Z, et al. Epithelial mesenchymal transition in embryonic development, tissue repair and cancer: a comprehensive overview[J]. J Clin Med, 2017, 7(1):1-25.
[15] Yang MH, Chen CL, Chau GY, et al. Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma[J]. Hepatology, 2009, 50(5):1464-1474.
[16] Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer[J]. Nat Rev Mol Cell Biol, 2019, 20(2):69-84.
[17] Hu S, Liu Y, You T, et al. Semaphorin 7A promotes VEGFA/VEGFR2-mediated angiogenesis and intraplaque neovascularization in ApoE(-/-) Mice[J]. Front Physiol, 2018, 30(9):1718-1730.
[18] Berretta M, Rinaldi L, Di Benedetto F, et al. Angiogenesis inhibitors for the treatment of hepatocellular carcinoma[J]. Front Pharmacol, 2016, 9(7):428-438.
[19] Gadaleta-Caldarola G, Divella R, Mazzocca A, et al. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond[J]. Future Oncol, 2015, 11(16):2263-2266.
[20] Chen J, Jin R, Zhao J,et al. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma[J]. Cancer Lett, 2015, 367(1):1-11.
[21] Dong J, Zhai B, Sun W, et al. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells[J]. PLoS One, 2017, 12(9):e0185088.
|